GLP-1对骨骼、中枢神经系统的影响及其机制研究进展  

The research of the effects of glucagon-like peptide-1 on bone metabolism and central nervous system and its mechanism

作　　者：刘璐[1] 戴如春[1] 

机构地区：[1]中南大学湘雅二医院代谢内分泌研究所,长沙410011

出　　处：《中华内分泌代谢杂志》2016年第6期527-530,共4页Chinese Journal of Endocrinology and Metabolism

基　　金：基金项目：国家自然科学基金（81270960）;教育部“新世纪优秀人才支持计划”（NCET-11-0507）;中华国际医学交流基金会项目（医基发[2014]14号）

摘　　要：骨质疏松症同糖尿病均是严重影响公共健康的重大疾病,且糖尿病患者发生骨折的风险升高。近年来,新型降糖药物胰升糖素样肽1（ GLP-1）类似物及其受体激动剂均已应用于治疗2型糖尿病。随着研究不断深入,GLP-1不仅具有降糖作用,还发挥促进骨形成、抑制骨吸收及神经保护/神经营养等效应,这提示其可能在骨质疏松症等其他疾病的治疗中也发挥重要作用。[Summary] Osteoporosis and diabetes mellitus are diseases which affect public heath severely, and osteoporotic fracture risk is increased in patients with diabetes. During recent years, new anti-diabetes drugs glucagon-like peptide-1（GLP-1） analogues and its receptor agonists had been used for diabetes treatment. As the research continues, besides of anti-diabetes, GLP-1 analogues are also found to play a role in bone metabolism and central nervous system by stimulating bone formation, inhibiting bone resorption, and nerve protection/nutrition, etc, suggesting that it may play an important role in the treatment of other diseases such as osteoporosis.

关 键 词：胰升糖素样肽1 骨形成 骨吸收 中枢神经系统 Glucagon-like peptide-1 

分 类 号：R977.15[医药卫生—药品]